Polaryx Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Polaryx Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has a cash flow conversion efficiency ratio of -0.125x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.37 Million) by net assets ($10.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Polaryx Therapeutics, Inc. Common Stock (2023–2025)
Cash flow conversion efficiency of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PLYX stock price for real-time trading data and today's change.
Polaryx Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Polaryx Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Polaryx Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see PLYX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Empress Royalty Corp
V:EMPR
|
0.125x |
|
Axcen Photonics
TWO:6530
|
0.067x |
|
Hansol Holdings Co Ltd
KO:004150
|
0.010x |
|
Quantum Graphite Ltd
AU:QGL
|
-0.115x |
|
Hasen-Immobilien AG
STU:ABHA
|
0.010x |
|
Banco Santander Río S.A
BA:BRIO
|
-0.322x |
|
AIAI Holdings Corporation Class A Common Stock
NASDAQ:AIAI
|
-0.002x |
|
NIP Group Inc. American Depositary Shares
NASDAQ:NIPG
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. Review Polaryx Therapeutics, Inc. Common Stock leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.57 Million | $-3.94 Million | -0.864x | -58.22% |
| 2024-12-31 | $4.71 Million | $-2.57 Million | -0.546x | -303.07% |
| 2023-12-31 | $1.28 Million | $-173.00K | -0.135x | -- |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more